Billionaire Investors Are Buying These 3 Artificial Intelligence (AI) Stocks Hand Over Fist
If you follow the world's wealthiest investors, you'll see a wide range of investing styles. Some focus on valuation. Others prioritize growth potential. A few look for arbitrage opportunities.
But there's at least one common denominator among many ultrarich investors these days: They like artificial intelligence (AI) stocks. Billionaires are buying these three AI stocks hand over fist.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »
1. Alphabet
Google parent Alphabet (NASDAQ: GOOG)(NASDAQ: GOOGL) stands out as a top pick for several billionaire investors. Izzy Englander might be the most bullish about the tech stock. His Millennium Management hedge fund upped its position in Alphabet by 150.8% in the first quarter of 2025.
Ken Griffin is another billionaire hedge fund manager who's enthusiastic about Alphabet stock. His Citadel Advisors increased its stake in the tech giant by 55.7% in Q1. Appaloosa's David Tepper also bought over 128,000 additional shares of Alphabet, bumping up his holding in the stock by 6.8%.
What do these billionaire investors like about Alphabet? Its valuation is probably near the top of the list. The stock trades at a forward price-to-earnings ratio below 19. None of the other so-called "Magnificent Seven" stocks comes anywhere close to such an attractive valuation.
Alphabet has also been showing that it's playing to win in the AI space. The company's Google Gemini 2.5 Pro ranks No. 1 overall on the LMArena leaderboard. Google Cloud continues to be the fastest-growing of the top three cloud service providers.
2. Amazon
There isn't as much of a consensus among billionaire investors when it comes to Amazon (NASDAQ: AMZN). Chase Coleman's Tiger Global Management upped its stake in the e-commerce and cloud service giant by 2.7% in Q1 and Englander's Millennium Management boosted its position in Amazon by 5.3%. However, Griffin's Citadel Advisors reduced its Amazon holding by 43.5%. Tepper's Appaloosa trimmed its position in Amazon by 3.5%.
But one billionaire loaded up on Amazon stock in the first quarter. George Soros bought more than 101,000 shares, increasing his hedge fund's stake in Amazon by 30.5%. Amazon is now the 11th largest holding in Soros Fund Management's $5.61 billion portfolio.
Soros probably likes Amazon's bottom-line improvement. In Q1, the company's earnings soared 64% year over year to $17.1 billion. Amazon has been laser-focused on improving profitability -- and its efforts are clearly paying off.
Amazon has also flexed its AI muscle. The company's Amazon Web Services unit still commands the largest market share in cloud services, thanks in part to its Amazon Bedrock platform that supports multiple AI models. Amazon recently introduced Alexa+, its next-generation AI assistant.
3. Meta Platforms
Meta Platforms (NASDAQ: META) elicits different views among billionaire investors as well. It's still the largest holding for Coleman's Tiger Global, but the hedge fund didn't buy or sell shares of Meta in Q1. Englander and Griffin seemed to sour on Meta somewhat, though, slashing their positions in the stock by 38.9% and 44.2%, respectively.
However, Tepper increased Appaloosa's stake in Meta by 12.2%, making it his portfolio's fifth largest holding. Steve Cohen, though, stood out as the biggest Meta bull in Q1. His Point 72 Asset Management increased its position in the Facebook and Instagram parent by a whopping 585%.
What might Cohen find so appealing about Meta? It could simply be the company's continued strength in the advertising market. A staggering 3.43 billion people used Meta's family of apps daily in Q1. The average price per ad shown to those users increased by 10% year over year.
I suspect that Cohen is enthusiastic about Meta's AI initiatives as well. Meta AI now has nearly 1 billion monthly active users. The company is also a leader in AI-powered smart glasses. CEO Mark Zuckerberg believes that glasses are "the ideal form factor" for AI.
Should you invest $1,000 in Meta Platforms right now?
Before you buy stock in Meta Platforms, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Meta Platforms wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $658,297!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $883,386!*
Now, it's worth noting Stock Advisor 's total average return is992% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of June 9, 2025
Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Keith Speights has positions in Alphabet, Amazon, and Meta Platforms. The Motley Fool has positions in and recommends Alphabet, Amazon, and Meta Platforms. The Motley Fool has a disclosure policy.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
34 minutes ago
- CTV News
‘You feel betrayed': Halifax professor sees spike in cheating by students using AI
Ed McHugh, a business and marketing professor at Dalhousie, Saint Mary's and Mount Saint Vincent universities in Halifax, speaks with CTV News on June 19, 2025. As artificial intelligence rises in popularity, one Halifax professor says he's noticed an unsettling trend over the last two years – students are using it to cheat on assignments. 'Having one student doing it is serious, but it's increasing,' said Ed McHugh, a business and marketing professor at Dalhousie, Saint Mary's and Mount Saint Vincent universities. 'I don't know the percentage, but it's more than one per cent.' McHugh recently posted about the issue on social media after he noticed a number of students cheated on an assignment. He could tell they had used AI to do the work for them. 'I was marking an assignment. They had to watch a video about a guy named Adam Smith and asked why he was treated the way he was. Unfortunately for them there was also an economist from the 18th century named Adam Smith and the answer that came back from a number of students was a history lesson on Adam Smith the economist from over 200 years ago,' explained McHugh. 'They didn't bother to watch the video. They just saw the words Adam Smith, did AI on Adam Smith, and gave me back a paragraph about Adam Smith the economist, which had nothing to do with the assignment.' Several commenters shared similar frustrations on McHugh's post. He says he's not alone in this and many other educators feel the same way. 'I feel disappointed any time a student cheats. As an educator you feel some sense of sadness and anger because you feel betrayed and you feel that they think you mustn't be that bright to catch some of this stuff,' said McHugh. However, McHugh says there are ways for educators to detect the use of this software, and some uses of AI are obvious. Another thing he's noticed as a professor is the decline of grammar skills over the last 30 years, which he says can actually be useful when trying to determine if someone used AI. If a student who struggles with grammar hands in a perfectly-worded assignment, McHugh says they likely used AI. 'When you have an email that is not written very well grammar-wise, but the attached assignment is in perfect English,' adds McHugh. McHugh also says the AI software he's noticed students using follows a certain format in its answers, so when someone copies the responses from it, it's noticeable. 'But then after that it gets really tricky and it comes down to your word versus the student's word,' he says. But there are ethical ways to use the software in schools. Some students like Juliette Savard use AI to enhance their writing and fact check. 'I think AI, when it is used the right way, is actually a really great tool,' said Savard. 'I use it all the time as a Google replacement because sometimes Google, it just links you to articles and it doesn't find you what you actually are looking for. And ChatGPT is really great for that because it will find you what you are actually looking for.' But when it comes to using AI to write her assignments, Savard says she would never take that chance. 'I would never use it to do my actual work because it's really stupid, if I can be honest. Give it a math equation, it doesn't know how to solve it,' she says. Her brother Gabriel Savard, who is in his third year at Dalhousie University, says English is not his first language, so for him, AI helps him better understand assignments. 'Usually when I see it, it's to get a better understanding of what the question is asking and put them in my words,' he says. 'English is not my first language so it helps to get that understanding of what is being asked of me.' Serena Dasilva is a third-year psychology student at Dalhousie University. She feels AI is useful for certain programs, but not all. 'For the arts specifically, I feel like it hinders your learning because you are relying a lot on social views, specifically how people interact with other people, and I feel like relying on AI kind of takes away from that,' says Dasilva. As for the rules of using the software in schools, they vary from classroom to classroom, and across different education levels. McHugh says, in post-secondary schools, professors should highlight their AI policies in their course outlines. 'So far, all of the policies I have read are not strong. The policies need to be stronger and a lot of them are discouraging the use of other softwares to detect whether AI has been used because those softwares aren't perfect either,' says McHugh. In general, one rule across the board is no plagiarism or cheating on work, whether using AI or not. If those rules aren't followed, there are serious consequences for students. 'On your first assignment, if you are caught and it's proven, you get zero for the assignment,' explains McHugh. 'If you're caught again in the course, you get zero for the course.' At the end of the day, McHugh says AI can be a great tool when used appropriately, but students who rely completely on AI are hindering their own learning. 'People go to school to become critical thinkers and that's why we teach because we want the generations behind us to be better thinkers and to make the world a better place,' he says. 'In some ways this helps, but in some ways this is being a deterrent to creating stronger students in the future.' For more Nova Scotia news, visit our dedicated provincial page
Globe and Mail
36 minutes ago
- Globe and Mail
VOO ETF News, 6/16/2025
How is VOO stock faring? The Vanguard S&P 500 ETF is down 1.03% in the past five days and 9.11% over the past year. Confident Investing Starts Here: According to TipRanks' unique ETF analyst consensus, determined based on a weighted average of its holdings' analyst ratings, VOO is a Moderate Buy. The Street's average price target of $611.49 implies an upside of 11.43%. Currently, VOO's five holdings with the highest upside potential are Caesars Entertainment (CZR), Interpublic Group of Companies (IPG), Moderna (MRNA), LKQ Corp. (LKQ), and PG&E Corp. (PCG). Meanwhile, its five holdings with the greatest downside potential are Palantir Technologies (PLTR), Franklin Resources (BEN), Cf Industries Holdings (CF), Tesla (TSLA), and Garmin (GRMN). Revealingly, VOO ETF's Smart Score is a seven, implying that this ETF will likely perform in line with the market. Power up your ETF investing with TipRanks. Discover the Top Equity ETFs with High Upside Potential, carefully curated based on TipRanks' analysis.
Globe and Mail
44 minutes ago
- Globe and Mail
With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC , June 20, 2025 /CNW/ -- USA News Group News Commentary – The costs of cancer drugs is skyrocketing, according to a recent report from Bloomberg. Analysts at Nova One Advisor estimate that the global oncology drugs market will grow at a 7.4% CAGR through to US$366.24 billion by 2034. Help doesn't appear to be coming from the public sector, as reports state that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For investors to note, plenty of oncology innovators have provided recent developments, including Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Immuneering Corporation (NASDAQ: IMRX), GRAIL, Inc. (NASDAQ: GRAL), Intensity Therapeutics, Inc. (NASDAQ: INTS), and Relay Therapeutics, Inc. (NASDAQ: RLAY). The global oncology market is expected to see strong growth over the next decade, with ResearchAndMarkets forecasting it to reach US$866.1 billion by 2034 at a 10.8% CAGR. A separate estimate from Vision Research Reports projects the market will surpass US$903.81 billion by the same year, growing at a 10.9% CAGR. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) has entered a new phase of leadership with the appointment of Jared Kelly as Chief Executive Officer and member of the Board. Kelly brings a background in high-stakes biotech transactions and strategic immuno-oncology development, positioning him to guide the company through its next stage of clinical and business evolution. Before joining Oncolytics, Kelly served as General Counsel at Ambrx Biopharma, where he played a key role in its $2 billion acquisition by Johnson & Johnson. His earlier work includes advising life sciences firms on licensing, partnerships, and M&A while at Kirkland & Ellis LLP and Lowenstein Sandler LLP. Now leading Oncolytics, he steps into a company advancing pelareorep, a virus-based immunotherapeutic designed to work synergistically with checkpoint inhibitors and other agents across a range of solid and blood cancers. "Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications. Importantly, the data show that pelareorep creates a robust immunologic response in difficult tumors and increases survival in a patient population where survival has historically evaded most patients," said Jared Kelly , CEO of Oncolytics Biotech. "With a renewed focus and sharpened clinical development plan, we believe we will move pelareorep forward effectively and efficiently to a place where potential partners will see the value of a de-risked immunotherapy. I am excited to get to work accelerating development and unlocking significant value for stakeholders." Kelly's appointment signals a clear strategic focus: advancing pelareorep toward key late-stage milestones through a capital-conscious approach that remains open to strategic collaboration. Pelareorep currently holds FDA Fast Track designation for both metastatic pancreatic ductal adenocarcinoma (mPDAC) and HR+/HER2- metastatic breast cancer (mBC) —a rare dual recognition that underscores its regulatory momentum. Across multiple studies, the virus-based therapy has demonstrated consistent immune activation, broad combinability with checkpoint inhibitors and chemotherapies, and encouraging response rates in challenging cancer types. In mPDAC, pelareorep has achieved over 60% objective response rates in tumor-evaluable patients across Phase 1 and 2 trials—more than double what's typically seen in historical benchmarks. Separate analyses also reported two-year survival rates four to six times higher than control arms or prior studies. In HR+/HER2- mBC, two randomized Phase 2 trials (IND-213 and BRACELET-1) showed survival benefits supportive of further investigation. Meanwhile, a Phase 2 cohort in anal cancer pairing pelareorep with a checkpoint inhibitor reported partial or complete responses in nearly half of evaluable patients—substantially higher than historical norms for monotherapy in this setting. "Mr. Kelly's vision and track record is an extraordinary fit with the standout clinical data pelareorep has generated to date," said Wayne Pisano , Chair of the Board and outgoing Interim CEO of Oncolytics. "We believe Mr. Kelly's well-documented ability to prioritize clinical program development, execute successful financings, and attract the attention of large industry peers will help maximize Oncolytics' potential to deliver transformative outcomes for patients and exceptional value for investors." Kelly's compensation package includes equity grants and milestone-linked incentives tied to future financings and potential strategic transactions—aligning leadership priorities with long-term shareholder interests. The structure signals a commitment to advancing both clinical and corporate goals while preserving balance sheet discipline and maintaining appeal for potential partners. With multiple cohorts progressing in the GOBLET study—including those in pancreatic and anal cancer supported by external funding and regulatory engagement— Oncolytics is positioned to move forward with a combination of scientific momentum, financial agility, and renewed strategic focus. In other recent industry developments and happenings in the market include: Immuneering Corporation (NASDAQ: IMRX) reported positive Phase 2a data for atebimetinib (IMM-1-104) in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients. At six months, the study showed 94% overall survival and 72% progression-free survival in 34 patients, with no median OS or PFS reached yet. "These exceptional data demonstrate the potential of atebimetinib plus mGnP to dramatically extend the lives of patients with advanced pancreatic cancer," said Ben Zeskind , Ph.D., Co-founder and CEO of Immuneering. "Our ultimate goal is to help cancer patients outlive their disease, and today's announcement represents an important milestone on that journey." The combination also demonstrated a 39% overall response rate, an 81% disease control rate, and a notably favorable tolerability profile. Many patients experienced deep, durable tumor regressions, including lesions rendered undetectable. The regimen was well tolerated, with an adverse event profile suggesting potential best-in-class positioning among MEK inhibitors. GRAIL, Inc. (NASDAQ: GRAL), recently announced strong top-line results from the PATHFINDER 2 registrational study evaluating its Galleri® multi-cancer early detection test in over 25,000 adults. "We are delighted to see very encouraging performance of the Galleri MCED test as a cancer screening tool in broad intended use populations of asymptomatic adults over 50 years of age in both the PATHFINDER 2 study and the NHS-Galleri trial's prevalent screening round," said Josh Ofman , MD, MSHS, President at GRAIL. "We would like to extend our sincere gratitude to all of the participants and investigators in both of these pivotal studies, who are collectively helping to realize the potential of this groundbreaking technology for population-scale multi-cancer early detection and move the field forward." The study showed a substantially higher positive predictive value (PPV) compared to the original PATHFINDER trial, with consistent specificity and cancer signal origin accuracy, and no serious safety concerns reported. GRAIL plans to submit these results to the FDA as part of its ongoing premarket approval process under Breakthrough Device Designation. Intensity Therapeutics, Inc. (NASDAQ: INTS) announced that the first patients in its ongoing Phase 2 INVINCIBLE-4 trial achieved high levels of tumor necrosis within eight days of receiving two doses of INT230-6, before starting standard-of-care immunochemotherapy for triple-negative breast cancer (TNBC). "We are excited to see that INT230-6 is achieving meaningful levels of necrosis in patients with evidence of immune activation," said Lewis H. Bender , President and CEO of Intensity. "TNBC patients risk their lives to achieve a pCR, and about forty percent fail to achieve the desired result." MRI scans showed substantial tumor destruction and inflammation, suggesting immune activation following direct intratumoral injection. The randomized study compares INT230-6 followed by standard treatment versus standard treatment alone, with pathological complete response (pCR) as the primary endpoint. Relay Therapeutics, Inc. (NASDAQ: RLAY) reported updated interim data from its Phase 1/2 study of RLY-2608 plus fulvestrant, showing a median progression-free survival (PFS) of 11.0 months in second-line patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer. "We are encouraged by the consistency of these updated RLY-2608 + fulvestrant data, which continue to show the potential benefit of a mutant-selective PI3Kα inhibitor for improving both the tolerability profile and progression free survival compared to standard of care," said Don Bergstrom , M.D., Ph.D., President of R&D at Relay Therapeutics. "We look forward to starting the first mutant-selective PI3Kα Phase 3 trial, ReDiscover-2, in the middle of this year." Among patients at the recommended Phase 3 dose, the clinical benefit rate reached 67%, and 39% had confirmed partial responses, with notably higher response rates in those with kinase mutations. The combination maintained a favorable tolerability profile, with low rates of high-grade adverse events and minimal treatment discontinuations. DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
